Shinji Nakade
Mishima, 6188585, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Preventive and Therapeutic Efficacy of ONO-4641, a Selective Agonist for Sphingosine 1-Phosphate Receptor 1 and 5, in Preclinical Models of Type 1 Diabetes Mellitus.
Journal: Biological & pharmaceutical bulletin
Published: February 01, 2021
Discovery of a 1-Methyl-3,4-dihydronaphthalene-Based Sphingosine-1-Phosphate (S1P) Receptor Agonist Ceralifimod (ONO-4641). A S1P1 and S1P5 Selective Agonist for the Treatment of Autoimmune Diseases.
Journal: Journal of medicinal chemistry
Published: November 10, 2017
Discovery of a Slow Tight Binding LPA1 Antagonist (ONO-0300302) for the Treatment of Benign Prostatic Hyperplasia.
Journal: ACS medicinal chemistry letters
Published: September 19, 2017
A new CysLT1 and CysLT2 receptors-mediated anaphylaxis guinea pig model.
Journal: Prostaglandins, leukotrienes, and essential fatty acids
Published: January 06, 2017
Discovery of ONO-7300243 from a Novel Class of Lysophosphatidic Acid Receptor 1 Antagonists: From Hit to Lead.
Journal: ACS medicinal chemistry letters
Published: June 01, 2016
Effects of ONO-6950, a novel dual cysteinyl leukotriene 1 and 2 receptors antagonist, in a guinea pig model of asthma.
Journal: European journal of pharmacology
Published: May 14, 2015
Crystal Structure of Antagonist Bound Human Lysophosphatidic Acid Receptor 1.
Journal: Cell
Published: December 03, 2014
A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension.
Journal: PloS one
Published: December 03, 2013
Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis.
Journal: Clinical and experimental immunology
Published: August 20, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026